Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.

Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The ...

At J.P. Morgan 2026, Pfizer CEO Albert Bourla positioned the company as a post-COVID operator focused on disciplined ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

In the latest close session, Pfizer (PFE) was up +1.63% at $25.56. This move outpaced the S&P 500's daily loss of 0.53%. On ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Pfizer Inc. (NYSE:PFE) ranks among the best stocks under $25 to buy now. Citing the company’s cautious 2026 outlook, BMO ...

Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched ...

Pfizer Inc. (PFE) named oncology chief and company veteran Chris Boshoff as its new chief scientific officer on Wednesday, replacing Mikael Dolsten starting Jan. 1. The drug company had been searching ...

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

At Pfizer, the certification recognises the company’s Analytics Gateway and broader data science ecosystem, where teams work ...